OR WAIT null SECS
December 09, 2021
Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.
December 01, 2021
Analytical methods need a boost to ensure quality control for cell and gene therapies.
November 10, 2021
Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.
November 08, 2021
Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.
October 22, 2021
A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.
October 14, 2021
Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California.
October 07, 2021
The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.
September 14, 2021
Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.
AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.
August 19, 2021
Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.